Lundbeck's Serdolect faces US panel scrutiny
This article was originally published in Scrip
Executive Summary
The US FDA's psychopharmacologic drugs advisory panel will evaluate the safety and efficacy of Lundbeck's schizophrenia drug Serdolect (sertindole) on April 7th.